Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
2
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
0 competitors in Neuromyelitis Optica Spectrum Disorder
View Full LandscapeTarget Indication
Neuromyelitis Optica Spectrum Disorder
Clinical Trial
NCT04660539Last updated: 1/9/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.
Enspryng
Satralizumab (Enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (IST) for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 IgG (AQP4-IgG) seropositive.